Cyclophosphamide is an anti-neoplastic chemotherapy drug which, when administered to animals during the gestational period, provokes visceral, skeletal and external malformations. Copaiba oil obtained from Copaifera L. genus is traditionally used in popular medicine for its anti-inflammatory and antimicrobial activities. However, the effect of copaiba oil onteratogenesis remains unknown. This study aimed to investigate the possible protector effects of copaiba oil on the model of teratogenesis induced by cyclophosphamide in mice. Pregnant female Swiss mice were divided into 8 groups (n = 15). Three groups received copaiba oil, via gavage, in the following doses: 0.3 mL•Kg −1 , 0.6 mL•Kg −1 and 0.9 mL•Kg −1 (b.w.), associated to phosphate-buffered saline (PBS), intraperitoneal (i.p.). The negative control group received medium chain triglyceride (MCT) and PBS. The positive control group received cyclophosphamide (30 mg •Kg −1 (b.w.) ) and MCT. The three treatment groups called associated groups (A) received one of the doses of copaiba oil, via gavage and an associated dose of cyclophosphamide intraperitoneally. Copaiba oil presented a protective effect against teratogenesis induced by cyclophosphamide in the following skeletal structures: metacarpals, forepaws proximal phalanges, and tail vertebras. It also reduced the hydrocephalus frequency. These data suggest that copaiba oil could be a potential candidate for an anti-teratogenic agent.
Introduction
Fetal development abnormalities can be caused by drugs, pollutants, radiation and diseases that induce oxidative stress and production of free radicals [1] [2] . In experimental models, oxidative stress can be induced by cyclophosphamide, a drug used in anti-neoplastic chemotherapy and in the treatment of autoimmune diseases. Metabolism of cyclophosphamide at mitochondrial level through the P450 enzymes from the cytochrome system generates two teratogenic metabolic products-acrolein and phosphoramide mustard [3] . In addition to direct cytotoxicity of the intermediate and final metabolic products, the drug also produces teratogenic effects by inhibiting DNA synthesis and provoking apoptosis induced by oxidative stress [4] - [6] . Administration of cyclophosphamide to animals during the gestational period causes delayed fetal development, in addition to visceral, skeletal and external malformations, particularly in the members and in the head [7] - [9] . Ashby and co-workers showed that inhibition of the P450 cytochrome system, induction of antioxidant enzymes, or the use of antioxidant substances reduced the embryotoxic effects of cyclophosphamide and other substances known to cause oxidative stress in animal models [6] - [8] [10] .
Copaiba oil is a resin-oil extract obtained from several species of Copaifera L. genus which is traditionally used in South American popular medicine as it demonstrates anti-inflammatory and antimicrobial activities. The main components of the oil are sesquiterpenes and diterpenes, substances that have been shown to possess antioxidant activity both in vivo and in vitro [6] [11] . Some sesquiterpenoid substances inhibit the embryolethal and teratogenic effects of cyclophosphamide administered to pregnant female rats, probably indirectly by inhibiting the reactions catalyzed by CYP2B1 [6] . This study aimed to investigate the possible protector effects of copaiba oil on the model of teratogenesis induced by cyclophosphamide in mice.
Methods

Animals
Male and nulliparous female Swiss mice (Mus musculus), weighing approximately 35 grams, supplied by the Central Vivarium of the Biological Sciences Center of the State University of Londrina (UEL), were used in the experiments. The animals were acclimatized for a 7-day period at the animal house, prior to the experiments. Animals were housed in standard polypropylene cages, containing wood shavings as bedding, with water and food ad libitum, under controlled light and temperature conditions (12 hours light/dark, at 22˚C ± 2˚C). The experiment was conducted according to the norms of the Ethics Committee in Animal Experimentation of UEL (CEUA-UEL) and registered under the protocol number 10036.2012.10.
Mating Procedure
Mating was performed by placing four females into the cage of one male overnight, after which females were examined for evidence-a vaginal copulatory plug. Upon detection of plugs, the females were separated and day 0 of pregnancy (PG0) designated. Pregnant females were randomly divided into 8 experimental groups of 15 animals, with a total of 120 females used in this experiment.
Study Design
Three (satellite) groups received Vid'Amazon copaiba oil (CO) extracted from Copaifera sp. via gavage in one of the following concentrations: Group CO0. ) of copaiba oil was selected after literature consultation [12] .
The CO treatment extended from the 8 th to the 12 nd day of the gestational period, and on the 10 th day, phosphate-buffered saline was intraperitoneally (i.p.) administered to animals of the CO0.3, CO0.6 and CO0.9 groups. Negative control group animals received medium chain triglyceride (MCT), by gavage, (this corresponds to the vehicle used to dilute the copaiba oil), in addition to PBS, under the same previously described experimental procedures. The positive control group received MCT from the 8 th to the 12 th days similar to the other experimental groups, in addition to a single dose of intraperitoneally administered cyclophosphamide (CP) 30 mg•Kg −1 (b.w.) on the 10 th pregnancy day. In order to evaluate the protective effect of copaiba oil on the alterations caused by CP during intra-uterine development, three (treatment) groups (A1, A2 and A3) received one of the three doses of copaiba oil from the 8 th to 12 th day of pregnancy in addition to a single dose of cyclophosphamide (CP) 30 mg•Kg −1 (b.w.) on the 10 th day of pregnancy. Pregnant females were weighed throughout the pregnancy for the evaluation of maternal weight gain. On day 18 of pregnancy, dams were euthanized by cervical dislocation, and laparotomies were performed. Gravidic uteri together with their contents were weighed. Fetuses were then removed and examined for: the number of live and dead fetuses, fetal and placental weight, and fetal length. Systematic analysis under a dissecting stereomicroscope was also performed to detect any external malformations. The emptied uteri were then examined for the presence of resorptions, and number of implantation sites determined using the Salewski method [13] . Postimplantation loss was calculated as follows: (number of implantations − number of live fetuses) × 100/number of implantations and fetal viability by: number of live fetuses/number of implantations. The adequacy of fetal weight to pregnancy age was determined by following the method established by Calderon [14] . Half of the fetuses of each litter were randomly taken and fixed in Bodian for visceral analysis. The remaining half were fixed in acetone and subjected to skeletal analysis using the Alizarin red technique [15] .
Visceral analysis of the thorax and abdomen was conducted following a combination of cuts/micro-dissections proposed by Barrow and Taylor [16] . The head visceral study was performed using strategic cuts proposed by Wilson [17] . The fetuses submitted to skeletal analysis were evaluated for: skull, sternum, vertebras, ribs, scapular and pelvic waists, phalanges, metacarpals and metatarsals abnormalities, according to the methodology described by Taylor [18] .
Absolute data with normal distribution were analyzed by ANOVA (variance analysis) complemented with the Tukey or the student T test. Those with abnormal distribution were analyzed by Kruskal-Wallis, complemented by the Dunn test or Mann-Whitney test. A 5% significance level was considered. The frequency difference between groups treated with cyclophosphamide only and the groups treated with cyclophosphamide associated with different doses of copaiba oil was analyzed by the chi-square test.
Results
Administration of MCT, different doses of copaiba oil, cyclophosphamide and the association of cyclophosphamide and copaiba oil did not induce maternal toxicity or alterations in the females' reproductive performance ( Table 1 ). The administration of copaiba oil at the three doses did not cause any alterations in fetal development. Cyclophosphamide administration induced alterations in the developmental pattern of fetuses and placentas, which were not reverted by the association with copaiba oil ( Table 2) .
Copaiba oil did not cause skeletal, external or visceral alterations in any of the analyzed fetuses. The most frequent external alterations caused by the administration of cyclophosphamide were cleft palate, exophthalmos, polydactyly and syndactyly. The administration of copaiba oil inhibited polydactyly at the forepaws ( Table 3) .
Cyclophosphamide caused skeletal malformations in the head, thorax, scapular and pelvic waists ( Table 4  and Table 5 ), characterized by the absence of formation, malformation (irregular forms) and reduced ossification. Although the administration of copaiba oil did not exert any effect on the reduced ossification, there was a reduction in the absent structures frequency, especially in the skull (basisphenoid and basiocciptal bones) and the irregular or malformed structures-hyoid, vertebras and the sternum ( Table 4) .
The analysis of ossification centers at hind and forepaws and at tail vertebras demonstrated that the administration of copaiba oil presented a protective effect against teratogenesis induced by cyclophosphamide at metacarpals, proximal phalanges in forepaws and at tail vertebras. The administration of cyclophosphamide inhibited the ossification of distal phalanges in both hind and forepaws, and reduced proximal phalanges in hind paws and metatarsal ossification without any protective effect of the copaiba oil ( Table 6 ).
The visceral analysis showed a significant reduction of hydrocephalus frequency caused by the administration of cyclophosphamide in animals treated with copaiba oil ( Table 7) .
Discussion
The therapeutic effects of some phytotherapeutic substances have been attributed to the presence of natural antioxidant components that act by increasing the expression of endogenous antioxidant systems, either by acting as free radical scavengers or by inhibiting free radical formation [6] [19]- [23] . Antioxidant agents reduce the toxic effects of free radicals and may reduce the teratogenic effect of oxidative stress in the developing fetus [7] The values are represented in average ± standard deviation. The statistical description of the groups was made using the Mann-Whitney-U test, followed by the Dunn test (non-parametric data). The minimum significance level considered was p < 0.05. MCT: animals treated with MCT (negative control), CO0.3: animals treated with 0.3 grams of copaiba oil; CO0.6: animals treated with 0.6 grams of copaiba oil; CO0.9: animals treated with 0.9 grams of copaiba oil; CP: animals treated with cyclophosphamide; A0.3: animals treated with cyclophosphamide and 0.3 g of copaiba oil; A6: animals treated with cyclophosphamide and 0.6 g of copaiba oil; A0.9: animals treated with cyclophosphamide and 0.9 g of copaiba oil. Table 2 . Effects of copaiba oil and cyclophosphamide on intra-uterine development. The values are represented in average ± standard deviation. The statistical description of the groups was made using ANOVA test, followed by Tukey-Kramer test (parametric data). The minimal significance level considered was p < 0.05. MCT: animals treated with MCT (negative control), CO0.3: animals treated with 0.3 grams of copaiba oil; CO0.6: animals treated with 0.6 grams of copaiba oil; CO0.9: animals treated with 0.9 grams of copaiba oil; CP: animals treated with cyclophosphamide; A0.3: animals treated with cyclophosphamide and 0.3 g of copaiba oil; A6: animals treated with cyclophosphamide and 0.6 g of copaiba oil; A0.9: animals treated with cyclophosphamide and 0.9 g of copaiba oil. a p < 0.005 significant statistical difference in comparison to MCT group. [10] . For example, the administration of indo-3-carbinol, an antioxidant agent found in raw vegetables, to pregnant female mice exposed to cyclophosphamide during the organogenesis period, reduces the number of fetal malformations [10] . Furthermore, in vitro studies which involved the addition of ginseng to mice embryo cultures demonstrated an increase in the expression of antioxidant enzymes and a reduction in malformations caused by ethanol induced oxidative stress [24] .
However, the administration of phytotherapeutic compounds during pregnancy must be evaluated with caution since some compounds of natural products may have proteratogenic effects [8] . For instance, the kaurenoic acid, a diterpene isolated from copaiba oleo-resin, showed cytotoxic and embryotoxic effects in developing sea urchin (Lytechinus variegatus) embryos, on tumor cell growth and on mouse and human erythrocytes [25] .
Copaiba oil is largely used in South American traditional medicine due to its anti-inflammatoratory [26] , antimicrobial [27] , antinociceptive [28] , antiparasitic [29] and antioxidant [30] activities. In the first step of this study, the cytotoxicity effect of copaiba oil on pregnant females and their offspring was evaluated. Our study showed that copaiba oil did not have a toxic or teratogenic activity for the administered doses. This corroborates the previous study by Sachetti [31] . The second stage of the study evaluated the toxicity of cyclophosphamide and the association between cyclophosphamide and copaiba oil in pregnant females. The administered dose of cyclophosphamide did not cause maternal toxicity or any significant alteration to reproductive patterns, but it did cause delayed development and fetal abnormalities, as previously described by other authors [3] [9] . The treatment of animals with copaiba oil submitted to the administration of cyclophosphamide did not attenuate the delay of fetal development, but significantly reduced the malformation frequency in structures derived from the neural tube, particularly the brain and some facial structures.
Copaiba oil is a phytotherapeutic extract that could be a strong candidate for an anti-teratogenic agent since it contains a class of substances known as terpenes (sesquiterpenes, diterpenes and triterpenes) whose antioxidant therapeutic properties have been previously described [6] [21]- [23] . It is probable that these substances increase the antioxidant enzyme system activity at phase II of biotransformation, or inhibit the activation of the P450 cytochrome system [3] [11] . The sesquiterpenoids (beta-caryophyllene, alfa-copaene, alfa-cadinene and alfahumulene) possess antioxidant effects by directly kidnapping free radicals (free radical scavengers), increasing the production of antioxidant enzymes, or inhibiting the production of nitric oxide [22] [23] [32]- [34] . Some sesquiterpenoid substances inhibit the embryolethal and teratogenic effects of cyclophosphamide administered to pregnant female rats [6] . In addition, plant extracts with high levels of beta-caryophyllene inhibit free radical formation and lipid peroxidation of critical mechanisms in lesions induced by free radicals [34] [35] .
Cyclophosphamide exerts neurotoxic effects, characterized by hydrocephalus, malformations of facial structures and members caused by the action of the drug and its metabolites [3] . In our study, we observed that the embryotoxic effects of cyclophosphamide on organs deriving from the neural tube were totally or partially reverted by the administration of copaiba oil. However, the administration of copaiba oil could not significantly reverse the alterations observed in members. Teratogenesis in embryonic tissues occurs in a selective way, which means that the cells comprising a determined tissue suffer alterations when exposed to a teratogen, while cells in other tissues are relatively resistant to the same teratogen. Some authors [4] [9] [36], demonstrated that teratogenesis caused by cyclophosphamide is related to the susceptibility of certain tissues to suffer apoptosis and alterations in the differential expression of the p53 gene, particularly in nervous tissues. Cytotoxic products of cyclophosphamide may be eliminated by the biotransformation system of phase II and by the action of antioxidants present at the mitochondrial matrix, such as the glutathione and catalase systems [8] [37] . The products of cyclophosphamide metabolized by P450 cytochrome, including acrolein and phosphoramide mustard, induce lipid peroxidation of mitochondrial membranes and liberation of c cytochrome that induces the activation of caspases 3, 8 and 9, and the p53 genes [38] . It is possible that the anti-teratogenic effects of copaiba oil are related to decrease in mitochondrial lesions caused by oxidative stress which makes the effects more evident on structures derived from the neural tube.
Conclusions
The results obtained in this study suggest that copaiba oil partially inhibits the teratogenic effects caused by cyclophosphamide. Although the teratogenicity of cyclophosphamide is mainly attributed to oxidative stress induced by the drug, the healing and cell proliferation inductor properties of copaiba oil also need to be investigated as a possible factor involved in the recovery of tissues damaged by the drug. This study opens possibilities for the use of copaiba oil components to inhibit the teratogenic effect caused by oxidative stress. This finding becomes particularly important considering the great number of systemic conditions caused by the environment and drugs that can induce oxidative stress and their deleterious effects on fetal development model. The values are represented in average ± standard deviation. The statistical description of the groups was made using the Mann-Whitney-U test, followed by the Dunn test (non-parametric data). The minimal significance level considered was p < 0.05. MCT: animals treated with MCT (negative control), CO0.3: animals treated with 0.3 grams of copaiba oil; CO0.6: animals treated with 0.6 grams of copaiba oil; CO0.9: animals treated with 0.9 grams of copaiba oil; CP: animals treated with cyclophosphamide; A0.3: animals treated with cyclophosphamide and 0.3 g of copaiba oil; A6: animals treated with cyclophosphamide and 0.6 g of copaiba oil; A0.9: animals treated with cyclophosphamide and 0.9 g of copaiba oil. Copaiba oil may also be used as an adjuvant in cancer chemotherapy, since concomitant nutritional therapy with antioxidants shows various benefits in the treatment of cancer patients, resulting in lowered side effects and allowing the continuation of cytotoxic treatment with diminished harm to the patient.
